KAPA
Kairos Pharma, Ltd.
AMEX: KAPA · HEALTHCARE · BIOTECHNOLOGY
$0.33
+1.48% today
Updated 2026-08-05
Market cap
$6.10M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.30
Dividend yield
—
52W range
$0 – $2
Volume
2.6M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C7.3
Quality
B+3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
14.3
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →211 stocks currently score above 75
Price targets
Analyst target
$7.00
+2021.21%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 14.27 — safe zone
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-1.04M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-1.05M | $-1.81M | $-2.60M | $-5.45M | $-1.65M |
| EPS | — | — | — | — | $-0.30 |
| Free cash flow | $-353000.00 | $81000.00 | $-3.96M | $-3.44M | $-1.04M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Kairos Pharma, Ltd. trades at $0.33. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 14.27, it sits in the safe zone.
Frequently asked questions
What is Kairos Pharma, Ltd.'s stock price?
Kairos Pharma, Ltd. (KAPA) trades at $0.33.
Is Kairos Pharma, Ltd. overvalued?
Kairos Pharma, Ltd. carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Kairos Pharma, Ltd. (KAPA)?
The 12-month analyst consensus target is $7.00, about 2021.2% above the current $0.33. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Kairos Pharma, Ltd.'s Altman Z-Score is 14.27, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeAMEX
CurrencyUSD
Quick metrics
P/S ratio—
ROE-76.19%
Beta—
50D MA$0.42
200D MA$0.67
Shares out0.02B
Float0.01B
Short ratio—
Avg volume2.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—